Blue Chip Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Blue Chip Partners's REGN Position: Q2 2026 in Review
Blue Chip Partners increased its Regeneron Pharmaceuticals (REGN) stake by 30% in Q2 2026, buying an estimated $212K and bringing the position to 1,341 shares worth $836K. The position accounts for 0.05% of the portfolio, ranked #104.
Blue Chip Partners first reported a position in REGN in Q1 2025 and has held it in 6 quarters since. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Blue Chip Partners held 1,341 shares of Regeneron Pharmaceuticals worth $836K as of Q2 2026.
- Blue Chip Partners bought 312 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $212K.
- Regeneron Pharmaceuticals made up 0.05% of Blue Chip Partners's portfolio in Q2 2026, its #104 holding.
- Blue Chip Partners first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
- 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Blue Chip Partners's 13F filing for Q2 2026, filed 14 Aug 2026.